Target intelligence / Profile preview

Sodium-coupled neutral amino acid transporter 3 (SLC38A3)

Target
SLC38A3
Molecular classification
Transporter, Symporter, System N amino acid transporter, Member of solute carrier family 38 (SLC38)
01

Overview

Sodium-coupled neutral amino acid transporter 3 (SLC38A3/SNAT3) is a plasma membrane transporter responsible for the electroneutral cotransport of neutral amino acids (primarily glutamine, histidine, and asparagine) together with sodium ions, coupled to proton antiport. It is highly expressed in the brain (astrocytes and blood-brain barrier), liver, kidney, heart, and skeletal muscle. In the CNS, it enables the glutamate–GABA–glutamine cycle essential for neurotransmitter recycling. In the kidney and liver, it facilitates ammonia detoxification and supports acid-base balance via renal ammoniagenesis. SLC38A3 is also implicated in glucose metabolism, nitrogen balance, and may play pathophysiological roles in conditions such as epilepsy, glioma, and metabolic acidosis. Dysfunction or altered expression of SLC38A3 has direct disease relevance in neurodevelopmental and metabolic disorders[1][2][4][6].

Other names
SLC38A3SNAT3SN1NAT1G17N-system amino acid transporter 1Na(+)-coupled neutral amino acid transporter 3Solute carrier family 38 member 3System N amino acid transporter 1Sodium-coupled neutral amino acid transporter 3
02

Mechanism of action

Amino acid transport modulation via sodium-coupled symport and H+ antiport activity. Drug mechanisms, if developed, would likely inhibit or modulate glutamine transport to affect neurotransmitter cycling, nitrogen metabolism, or cell proliferation.

03

Biological functions

Amino acid transport (specifically glutamine, asparagine, and histidine)Glutamate-GABA-glutamine cycle in brain (shuttling glutamine for neurotransmitter replenishment)Energy metabolism (substrate supply for gluconeogenesis and insulin regulation)Ammonia detoxification (hepatic and renal ammoniagenesis)Acid-base balance (renal response during metabolic acidosis)Glucose metabolismGestation (role in placenta)
04

Disease associations

Developmental and epileptic encephalopathy 102Non-specific early-onset epileptic encephalopathyCancer (e.g., glioma) (upregulation in gliomas)Chronic kidney disease (potential protection of podocytes)Metabolic acidosis-related kidney dysfunctionOther (possibly involved in glucose and nitrogen metabolism disorders)
05

Safety considerations

Disruption of glutamine, histidine, and asparagine homeostasis may impact neuronal function, hepatic ammonia detoxification, and renal acid-base balance—potential for CNS, metabolic, and renal side effects if targeted therapeuticallyPossibility of metabolic acidosis or neurological issues if transporter function is impairedBroad tissue expression suggests risk for off-target metabolic effects
06

Interacting drugs

No well-established direct pharmacological inhibitors or in-market drugs targeting SLC38A3 are documented as of the current evidence; research compounds and inhibitors may exist for research use, but no clinical agents are definitively described.
07

Biomarkers

Increased SNAT3 expression in advanced gliomas may serve as a biomarker for brain tumor diagnosis or progressionPotential marker in epileptic encephalopathies associated with SLC38A3 mutationsPossible renal biomarker for acidosis-induced ammoniagenesisNone mainstream for clinical patient selection

Beyond the preview

Go deeper on Sodium-coupled neutral amino acid transporter 3 (SLC38A3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sodium-coupled neutral amino acid transporter 3 (SLC38A3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call